TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens
Brief Summary: This is a randomized double-blind, controlled trial comparing two regimens of pre-abortion doxycycline. The aims of the study are to determine the serum levels of doxycycline when administered pre-operatively 4 hours or approximately 18 hours before a dilation and evacuation (D \& E) abortion. The hypotheses being tested are that subjects who receive doxycycline with food the night before an abortion will have adequate serum levels, but less nausea and vomiting compared to women who take the doxycycline on an empty stomach on the morning of the abortion. Subjects will either take 200mg doxycycline on the night before and 2 caps placebo with a sip of water on the morning of surgery or 2 caps placebo the night before and 200mg doxycycline on the morning of surgery with a sip of water. All capsules will look identical. Diaries, questionnaires and a 10cc sample of blood for doxycycline levels will be collected from the subjects at the time of surgery.


Options:
A: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
B: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens
Brief Summary: This is a randomized double-blind, controlled trial comparing two regimens of pre-abortion doxycycline. The aims of the study are to determine the serum levels of doxycycline when administered pre-operatively 4 hours or approximately 18 hours before a dilation and evacuation (D \& E) abortion. The hypotheses being tested are that subjects who receive doxycycline with food the night before an abortion will have adequate serum levels, but less nausea and vomiting compared to women who take the doxycycline on an empty stomach on the morning of the abortion. Subjects will either take 200mg doxycycline on the night before and 2 caps placebo with a sip of water on the morning of surgery or 2 caps placebo the night before and 200mg doxycycline on the morning of surgery with a sip of water. All capsules will look identical. Diaries, questionnaires and a 10cc sample of blood for doxycycline levels will be collected from the subjects at the time of surgery.


Options:
A: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Insulin Glargine on Glycemic Control, Morbidity, and Length of Stay in Hospitalized Subjects With Diabetes Receiving Enteral Nutrition
Brief Summary: The purpose of this study is to determine if the early initiation of a long acting insulin (i.e. glargine) with supplemental doses of short acting regular (SSR) insulin in hospitalized patients with diabetes who are fed using tube feedings reduces the frequency of high and low blood sugar levels when compared to use of SSR insulin alone.


Options:
A: Arm Label: IV insulin drip with target glucose 80 mg/dL - 130 mg/dL; Type: EXPERIMENTAL; Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL | Arm Label: Sub Q insulin to keep glucose less than 180 mg/dL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL | Intervention Type: DRUG; Name: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Assigned to Arm(s): IV insulin drip with target glucose 80 mg/dL - 130 mg/dL | Intervention Type: DRUG; Name: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL; Assigned to Arm(s): Sub Q insulin to keep glucose less than 180 mg/dL
B: Intervention Type: DRUG; Name: Glargine insulin vs regular insulin; Assigned to Arm(s): N/A
C: Arm Label: sliding scale regular insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: sliding scale regular insulin | Arm Label: glargine insulin and glulisine insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: glargine basal insulin and glulisine prandial insulin | Intervention Type: DRUG; Name: sliding scale regular insulin; Assigned to Arm(s): sliding scale regular insulin | Intervention Type: DRUG; Name: glargine basal insulin and glulisine prandial insulin; Assigned to Arm(s): glargine insulin and glulisine insulin
D: Arm Label: Bedtime supplementation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bedtime insulin Aspart (Novolog) | Arm Label: no bedtime supplementation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bedtime insulin Aspart (Novolog); Assigned to Arm(s): Bedtime supplementation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Screening for Chlamydia Surveillance
Brief Summary: This is a randomized controlled trial to determine whether a home screening test for chlamydia and gonorrhea will lead to increased use of screening tests and increased detection of sexually transmitted diseases.


Options:
A: Intervention Type: PROCEDURE; Name: Home sampling (urine test) for uro-genital C.trachomatis.; Assigned to Arm(s): N/A
B: Arm Label: Cervarix/Engerix-B A Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Cervarix/Engerix-B B Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group | Intervention Type: BIOLOGICAL; Name: Engerix-B; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group, Engerix-B Group
C: Arm Label: Home; Type: EXPERIMENTAL; Interventions: Behavioral: Home screening | Arm Label: Clinic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic screening | Intervention Type: BEHAVIORAL; Name: Home screening; Assigned to Arm(s): Home | Intervention Type: BEHAVIORAL; Name: Clinic screening; Assigned to Arm(s): Clinic
D: Intervention Type: BEHAVIORAL; Name: home testing kit; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Screening for Chlamydia Surveillance
Brief Summary: This is a randomized controlled trial to determine whether a home screening test for chlamydia and gonorrhea will lead to increased use of screening tests and increased detection of sexually transmitted diseases.


Options:
A: Intervention Type: PROCEDURE; Name: Self-collected vaginal swab for chlamydia testing; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Home sampling (urine test) for uro-genital C.trachomatis.; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: home testing kit; Assigned to Arm(s): N/A
D: Arm Label: Home; Type: EXPERIMENTAL; Interventions: Behavioral: Home screening | Arm Label: Clinic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic screening | Intervention Type: BEHAVIORAL; Name: Home screening; Assigned to Arm(s): Home | Intervention Type: BEHAVIORAL; Name: Clinic screening; Assigned to Arm(s): Clinic

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventive Health Education for Women of Reproductive Age
Brief Summary: The purpose of this study is to determine whether "video doctor" programs can effectively deliver preventive health messages to women of reproductive age while they wait to be seen in urgent care settings. In this study, the specific hypotheses being tested are: 1) is the video doctor program effective in improving women's knowledge about emergency contraception, and 2) is the video doctor program effective in improving women's knowledge about the importance of folate.


Options:
A: Arm Label: 400 micrograms of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Arm Label: 4mg of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Intervention Type: DRUG; Name: Folic acid: 4 mg versus 0.4 mg per day; Assigned to Arm(s): 400 micrograms of folic acid, 4mg of folic acid
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: "video doctor," computer module | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "video doctor," computer module | Intervention Type: BEHAVIORAL; Name: "video doctor," computer module; Assigned to Arm(s): 1, 2
D: Arm Label: folic acid 4 mg; Type: EXPERIMENTAL; Interventions: Drug: folic acid | Arm Label: folic acid 0.4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: folic acid | Intervention Type: DRUG; Name: folic acid; Assigned to Arm(s): folic acid 4 mg | Intervention Type: DRUG; Name: folic acid; Assigned to Arm(s): folic acid 0.4 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventive Health Education for Women of Reproductive Age
Brief Summary: The purpose of this study is to determine whether "video doctor" programs can effectively deliver preventive health messages to women of reproductive age while they wait to be seen in urgent care settings. In this study, the specific hypotheses being tested are: 1) is the video doctor program effective in improving women's knowledge about emergency contraception, and 2) is the video doctor program effective in improving women's knowledge about the importance of folate.


Options:
A: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine/folic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine/placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: "video doctor," computer module | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "video doctor," computer module | Intervention Type: BEHAVIORAL; Name: "video doctor," computer module; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ADHD Symptoms in Autism: Cognition, Behavior, Treatment
Brief Summary: This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD. The study also examined the effectiveness of a range of doses of methylphenidate in improving cognitive and behavioral outcomes in children with both ASD and ADHD.


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo
C: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ADHD Symptoms in Autism: Cognition, Behavior, Treatment
Brief Summary: This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD. The study also examined the effectiveness of a range of doses of methylphenidate in improving cognitive and behavioral outcomes in children with both ASD and ADHD.


Options:
A: Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ADHD Symptoms in Autism: Cognition, Behavior, Treatment
Brief Summary: This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD. The study also examined the effectiveness of a range of doses of methylphenidate in improving cognitive and behavioral outcomes in children with both ASD and ADHD.


Options:
A: Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo
B: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine (Zyprexa) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: olanzapine (Zyprexa); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients
Brief Summary: This twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective disorder, major depression or bipolar disorder with psychotic features. This study evaluates symptom response as well as general health indicators such as body mass index, glucose, prolactin, and cholesterol levels at baseline, month (M)1, M3, M6 and M12.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Xenical + behavioral intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral intervention + placebo | Intervention Type: DRUG; Name: Xenical + behavioral intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral intervention + placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine versus risperidone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine versus risperidone | Intervention Type: DRUG; Name: olanzapine versus risperidone; Assigned to Arm(s): 1, 2
C: Arm Label: Melatonin; Type: EXPERIMENTAL; Interventions: Drug: Melatonin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): Melatonin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Protein Supplementation and Resistance Exercise in Hemodialysis Patients
Brief Summary: The objective of this study is to determine how protein supplementation, with or without exercise, affects functional capacity, strength, body composition, and physical activity in hemodialysis patients.


Options:
A: Arm Label: Ceprolac; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ceprolac | Arm Label: Dietary counseling (DC); Type: PLACEBO_COMPARATOR; Interventions: Other: Dietary counseling (DC) | Intervention Type: DIETARY_SUPPLEMENT; Name: Ceprolac; Assigned to Arm(s): Ceprolac | Intervention Type: OTHER; Name: Dietary counseling (DC); Assigned to Arm(s): Dietary counseling (DC)
B: Arm Label: Usual Care Protocol; Type: OTHER; Interventions: Dietary Supplement: Nutritional Supplement | Arm Label: Intensive Protocol; Type: OTHER; Interventions: Dietary Supplement: Nutritional Supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional Supplement; Assigned to Arm(s): Intensive Protocol, Usual Care Protocol
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: nutritional supplementation | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: nutritional supplementation, Behavioral: exercise | Intervention Type: DRUG; Name: nutritional supplementation; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): 3
D: Arm Label: treated group; Type: EXPERIMENTAL; Interventions: Other: training on ergonomic bicycle, Drug: Testosterone, Drug: Oral nutritional supplementation, Drug: n3 polyunsaturated fatty acid | Arm Label: control group; Type: OTHER; Interventions: Drug: Oral nutritional supplementation | Intervention Type: OTHER; Name: training on ergonomic bicycle; Assigned to Arm(s): treated group | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): treated group | Intervention Type: DRUG; Name: Oral nutritional supplementation; Assigned to Arm(s): control group, treated group | Intervention Type: DRUG; Name: n3 polyunsaturated fatty acid; Assigned to Arm(s): treated group

Answer: C